Veltuzumab

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Veltuzumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD20
Identifiers
CAS Number 728917-18-8 N
ATC code none
UNII BPD4DGQ314 YesY
Chemical data
Formula C6458H9918N1706O2026S46
Molecular mass 145.3 kg/mol
 NYesY (what is this?)  (verify)

Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma.[1][2] As of December 2011, it is undergoing Phase I/II clinical trials.[3] When used with milatuzumab it showed activity.[4]

This drug was developed by Immunomedics, Inc. and was originally known as IMMU-106.[5]

In August 2015 the US FDA granted it orphan drug status for immune thrombocytopenia (ITP).[6] A phase II trial is planned to run for 5 years.[6]

See also

References

  1. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Veltuzumab, American Medical Association.
  2. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  3. ↑ Clinical trial number NCT00546793 for "Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL" at ClinicalTrials.gov
  4. ↑ The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma.
  5. ↑ Handbook of Therapeutic Antibodies. p791
  6. ↑ 6.0 6.1 FDA grants orphan drug designation to veltuzumab for ITP


<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.
Retrieved from "https://infogalactic.com/w/index.php?title=Veltuzumab&oldid=707387448"